Cannabidiol: A Moving Target for Regulators and Health Care Practitioners
This activity is for pharmacists and is sponsored by Postgraduate Healthcare Education, LLC (PHE).
There has been no commercial support for this activity.
Gerald Gianutsos, PhD, JD
Emeritus Associate Professor of Pharmacology
University of Connecticut
School of Pharmacy
Gerald Gianutsos, PhD, JD, hereby state that he has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
The following reviewer, Jeannette Wick, RPh, MBA, hereby states she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
Susanne Batesko, RN, BSN, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 2.0 hours (0.20 ceu)
Type of Activity: Knowledge
Fee Information: $6.97
Estimated time to complete activity: 120 minutes
October 9, 2019
October 9, 2022
This activity has been designed to meet the needs of pharmacists.
HOW TO OBTAIN CREDIT
During the period October 9, 2019 through October 9, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Cannabidiol (CBD), a compound found in marijuana which does not produce the "high" associated with tetrahydrocannbinol (THC), has become an extremely popular and widely available therapy for a wide variety of disorders, although generally with little reliable evidence. Until recently, the use of CBD was restricted because of its status as a C-I controlled substance under federal law. This lesson will examine the changing regulatory landscape of this substance. The legal status of CBD is in flux mainly because of expanding medical marijuana programs at the state level, FDA approval of a form of CBD for treating pediatric seizure disorders, and the shift in the legal status of hemp. The increasing use and acceptance of CBD offers challenges for pharmacy staff which will be discussed.
To aid pharmacists and technicians with understanding the growing popularity of cannabidiol as a potential therapeutic entity and to update pharmacists and technicians on the conflicting and rapidly evolving regulatory status of this substance.
After completing this continuing education activity, the participant should be able to:
- Discuss the pharmacology, potential therapeutic uses and limitations of cannabidiol (CBD).
- Differentiate the regulatory distinction between approved and non-approved forms of CBD.
- Explain the DEA's and FDA's position on CBD and its historical context.
- Describe the recent events that have resulted in a shifting of the regulatory status of CBD.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.
Part of Pharmacist CE Library
1 year access - $97.00